Company Information

  

Address: 201 GROVE RD  
City: THOROFARE 
State: NJ 
Zip Code: 08086 
Telephone: 856-848-8698 

Description of Business

Primary SIC Code: 2835
(As filed with the SEC)  

Akers Biosciences, Inc. ("Akers," "we" or the "Company") develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. Akers believes it has advanced the science of diagnostics through the development of several innovative proprietary platform technologies that provide product development flexibility. All of Akers' rapid, single-use tests are performed in vitro (outside the body) and are designed to enhance patient well-being and reduce total outcome costs of healthcare. The Company's current product offerings and pipeline products focus on delivering diagnostic assistance in a wide variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory disease and infectious disease detection, as well as for on and off-the-job alcohol safety initiatives.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-0.45NAN/E
12/2017-0.61NAN/E
09/2017-0.59NAN/E
06/2017-0.40NAN/E
03/2017-0.52NAN/E
12/2016-0.61NAN/E
09/2016-1.18NAN/E
06/2016-1.69NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.05Total Liab/Total Assets0.16
Net Inc/Total Assets-0.53Total Liab/Inv Cap0.19
Net Inc/Inv Cap-0.64Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-1.48Interest Coverage RatioNA
Net Inc/Net Sales-1.48Curr Debt/EquityNA
Cash Flow/Net Sales-1.29LTD/EquityNA
SG&A/NetSales1.56Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover3.49Quick Ratio4.22
Inventory Turnover0.73Current Ratio5.26
Inventory Day Sales0.00Net Rec/Curr Assets0.17
Net Sales/Work Cap0.52Inv/Curr Assets0.20
Net Sales/PP&E16.71  

Income Statement (Millions)

  12/31/2017 9/30/2017 6/30/2017 3/31/2017
Total Revenues(Net Sales) 1.39 0.68 1.20 0.67
Cost of Goods Sold 0.57 0.32 0.26 0.26
Selling & Admin Exps 2.31 1.20 1.25 1.38
Operating Income -1.84 -1.18 -0.67 -1.36
Interest Exp NA NA NA NA
Pretax Income -2.61 -1.18 -0.67 -1.35
Other Income -0.77 -0.00 0.00 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.61 -1.18 -0.67 -1.35

Balance Sheet (Millions)

Assets 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Cash & Short Term Investments 5.45 0.15 1.21 2.24
Receivables - Total 1.62 1.25 1.05 0.54
Inventories - Total 1.85 2.09 2.17 2.17
Total Current Assets 9.32 3.98 4.91 5.33
Net Property, Plant & Equipment 0.24 0.24 0.26 0.26
Total Assets 10.89 5.53 6.56 7.11
Liabilities        
Accounts Payable 1.77 1.57 1.45 1.36
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 1.77 1.58 1.45 1.36
Long-Term Debt NA NA NA NA
Total Liabilities 1.77 1.58 1.45 1.36
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 1.76 0.00 0.00 0.00
Common Stock 110.65 104.63 104.62 104.59
Retained Earnings -103.28 -100.67 -99.50 -98.83
Treasury Stock NA NA NA NA
Total Stockholders' Equity 9.11 3.95 5.12 5.75
Total Liabilities and Stockholders' Equity 10.89 5.53 6.56 7.11

Cash Flow Summary (Millions)

Categories 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Net Cash Provided by Operating Activities -1.43 -1.06 -1.03 -1.56
Net Cash Provided by Investing Activities -5.02 1.00 -0.87 -0.12
Net Cash Provided by Financing Activities 6.75 0.00 0.02 3.70

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20133.58-1.43--
12/20144.43-3.13-0.66
12/20152.12-9.31-1.89
12/20162.96-3.30-0.61
12/20173.93-5.81-0.61
Growth Rates2.37----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18244,2244.49




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.